Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint ...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted ...
If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...
We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...
Stocktwits on MSN
Why is IMNM stock rising today?
Immunome said that the study met its primary endpoint, showing a significant improvement in progression-free survival ...
P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to ...
Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...
The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world leader in listeria-based cancer ...
Medicines enabled by NIH funding have been crucial for increasing life expectancy and health – dramatically decreasing deaths due to heart disease and stroke, improving cancer outcomes, controlling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback